Biblioteca Virtual em Saúde

Pesquisa | Influenza A (H1N1)

  • BIREME | OPAS | OMS logo
 

Histórico de pesquisa  ()

Sua seleção  ()

 0 documento(s) selecionado(s).

Refine sua pesquisa

Collapse All  Ocultar
Expand All  Mostrar
Áreas temáticas
Texto completo (41)
Idioma
Ano de publicação

Enviar por email

Você tem 0 documento(s) selecionado(s).

Nenhum documento selecionado

 
Resultados  1-12 de 53
1.

The pharmacological management of severe influenza infection - 'existing and emerging therapies'.

Autor(es): Mc Mahon, Aisling; Martin-Loeches, Ignacio
Fonte: Expert Rev Clin Pharmacol;10(1): 81-95, 2017 Jan.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27797595
Resumo: INTRODUCTION: Over the last century several influenza outbreaks have traversed the globe, most recently the influenza A(H1N1) 2009 pandemic. On each occasion, a highly contagious, virulent pathogen has emerged, leading to significant morbidity and mortality amongst those affected. Areas covered: Early antiviral therapy and supportive care is the mainstay of treatment. Treatment should be started as soon as possible and not delayed for the results of diagnostic testing. Whilst oseltamivir is (mais)
2.

Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.

Autor(es): Kossyvakis, A; Mentis, A-F A; Tryfinopoulou, K; Pogka, V; Kalliaropoulos, A; Antalis, E; Lytras, T; Meijer, A; Tsiodras, S; Karakitsos, P; Mentis, A F
Fonte: Eur J Clin Microbiol Infect Dis;36(2): 361-371, 2017 Feb.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27848039
Resumo: There was an increase in severe and fatal influenza cases in Greece during the 2011-2015 post-pandemic period. To investigate causality, we determined neuraminidase (NA) inhibitor susceptibility and resistance-conferring NA and hemagglutinin (HA) mutations in circulating influenza type A viruses during the pandemic (2009-2010) and post-pandemic periods in Greece. One hundred thirty-four influenza A(H1N1)pdm09 and 95 influenza A(H3N2) viruses submitted to the National Influenza Reference Lab (mais)
3.

Investigational hemagglutinin-targeted influenza virus inhibitors.

Autor(es): Zeng, Li-Yan; Yang, Jie; Liu, Shuwen
Fonte: Expert Opin Investig Drugs;26(1): 63-73, 2017 Jan.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27918208
Resumo: INTRODUCTION: Seasonal influenza and pandemic outbreaks typically result in high mortality and morbidity associated with severe economic burdens. Vaccines and anti-influenza drugs have made great contributions to control the infection. However, antigenic drifts and shifts allow influenza viruses to easily escape immune neutralization and antiviral drug activity. Hemagglutinin (HA)is an important envelope protein for the entry of influenza viruses into host cells, thus, HA-targeted agents ma (mais)
5.

Persistent Infection of Drug-resistant Influenza A Virus during Chemotherapy for Malignant Lymphoma.

Autor(es): Kawakami, Toru; Hirabayashi, Yukio; Kawakami, Fumihiro; Isobe, Rei; Kaneko, Naoto; Mimura, Yuto; Ito, Toshiro; Furuta, Kiyoshi; Shimazaki, Mami; Nakazawa, Hideyuki; Kitano, Kiyoshi
Fonte: Intern Med;55(13): 1807-10, 2016.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27374689
Resumo: We herein report the case of an 80-year-old man with malignant lymphoma who became persistently infected with influenza A virus. Although he was repeatedly treated with NA inhibitors, such as oseltamivir or peramivir, nasal cavity swab tests for influenza A antigen continued to be positive for more than 2 months. Virological analyses revealed that he was infected with the NA inhibitor-resistant A (H3N2) virus possessing an R292K substitution in the NA protein. These findings suggest that a (mais)
6.

A Computational Model for Docking of Noncompetitive Neuraminidase Inhibitors and Probing their Binding Interactions with Neuraminidase of Influenza Virus H5N1.

Autor(es): Chintakrindi, Anand S; Martis, Elvis A F; Gohil, Devanshi J; Kothari, Sweta T; Chowdhary, Abhay S; Coutinho, Evans C; Kanyalkar, Meena A
Fonte: Curr Comput Aided Drug Des;12(4): 272-281, 2016.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27412704
Resumo: BACKGROUND: With cases of emergence of drug resistance to the current competitive inhibitors of neuraminidase (NA) such as oseltamivir and zanamavir, there is a present need for an alternative approach in the treatment of avian influenza. With this in view, some flavones and chalcones were designed based on quercetin, the most active naturally occurring noncompetitive inhibitor. OBJECTIVE: We attempt to understand the binding of quercetin to H5N1-NA, and synthetic analogs of quercetin namel (mais)
7.

Novel spirothiazamenthane inhibitors of the influenza A M2 proton channel.

Autor(es): Arns, Steve; Balgi, Aruna D; Shimizu, Yoko; Pfeifer, Tom A; Kumar, Nag; Shidmoossavee, Fahimeh S; Sun, Sharon; Tai, Sheldon S-H; Agafitei, Olga; Jaquith, James B; Bourque, Elyse; Niikura, Masahiro; Roberge, Michel
Fonte: Eur J Med Chem;120: 64-73, 2016 Sep 14.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27187859
Resumo: The development of treatments for influenza that inhibit the M2 proton channel without being susceptible to the widespread resistance mechanisms associated with the adamantanes is an ongoing challenge. Using a yeast high-throughput yeast growth restoration assay designed to identify M2 channel inhibitors, a single screening hit was uncovered. This compound (3), whose structure was incorrectly identified in the literature, is an inhibitor with similar potency to amantadine against WT M2. A l (mais)
8.

Influenza Activity - United States, 2015-16 Season and Composition of the 2016-17 Influenza Vaccine.

Autor(es): Davlin, Stacy L; Blanton, Lenee; Kniss, Krista; Mustaquim, Desiree; Smith, Sophie; Kramer, Natalie; Cohen, Jessica; Cummings, Charisse Nitura; Garg, Shikha; Flannery, Brendan; Fry, Alicia M; Grohskopf, Lisa A; Bresee, Joseph; Wallis, Teresa; Sessions, Wendy; Garten, Rebecca; Xu, Xiyan; Elal, Anwar Isa Abd; Gubareva, Larisa; Barnes, John; Wentworth, David E; Burns, Erin; Katz, Jacqueline; Jernigan, Daniel; Brammer, Lynnette
Fonte: MMWR Morb Mortal Wkly Rep;65(22): 567-75, 2016 Jun 10.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27281364
Resumo: During the 2015-16 influenza season (October 4, 2015-May 21, 2016) in the United States, influenza activity* was lower and peaked later compared with the previous three seasons (2012-13, 2013-14, and 2014-15). Activity remained low from October 2015 until late December 2015 and peaked in mid-March 2016. During the most recent 18 influenza seasons (including this season), only two other seasons have peaked in March (2011-12 and 2005-06). Overall influenza activity was moderate this season, w (mais)
9.

Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016.

Autor(es): Takashita, Emi; Fujisaki, Seiichiro; Shirakura, Masayuki; Nakamura, Kazuya; Kishida, Noriko; Kuwahara, Tomoko; Shimazu, Yukie; Shimomura, Takeshi; Watanabe, Shinji; Odagiri, Takato
Fonte: Euro Surveill;21(24)2016 Jun 16.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27336226
Resumo: An influenza A(H1N1)pdm09 virus carrying a G147R substitution in combination with an H275Y substitution in the neuraminidase protein, which confers cross-resistance to oseltamivir and peramivir, was detected from an immunocompromised inpatient in Japan, March 2016. This dual H275Y/G147R mutant virus exhibited enhanced cross-resistance to both drugs compared with the single H275Y mutant virus and reduced susceptibility to zanamivir, although it showed normal inhibition by laninamivir.
10.

Adamantane - A Lead Structure for Drugs in Clinical Practice.

Autor(es): Spilovska, Katarina; Zemek, Filip; Korabecny, Jan; Nepovimova, Eugenie; Soukup, Ondrej; Windisch, Manfred; Kuca, Kamil
Fonte: Curr Med Chem;23(29): 3245-3266, 2016.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 27222266
Resumo: The adamantane moiety is the structural backbone of numerous compounds and its discovery launched a new field of chemistry studying the approaches to the synthesis as well as the physicochemical and biological properties of organic polyhedral compounds with practical application in the pharmaceutical industry. Adamantane derivatives have proven to be very potent compounds in a wide range of applications from systemic to topical therapy. This review summarizes the currently available adamant (mais)
11.

Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.

Autor(es): McKimm-Breschkin, Jennifer L; Fry, Alicia M
Fonte: Antiviral Res;129: 21-38, 2016 May.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26872862
Resumo: The International Society for Influenza and other Respiratory Virus Diseases (isirv) held its 4th Antiviral Group Conference at the University of Texas on 2-4 June, 2015. With emerging resistance to the drugs currently licensed for treatment and prophylaxis of influenza viruses, primarily the neuraminidase inhibitor oseltamivir phosphate (Tamiflu) and the M2 inhibitors amantadine and rimantadine, and the lack of effective interventions against other respiratory viruses, the 3-day programme (mais)
12.

Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.

Autor(es): Ruangrung, Kanyarat; Suptawiwat, Ornpreya; Maneechotesuwan, Kittipong; Boonarkart, Chompunuch; Chakritbudsabong, Warunya; Assawabhumi, Jirawatna; Bhattarakosol, Parvapan; Uiprasertkul, Mongkol; Puthavathana, Pilaipan; Wiriyarat, Witthawat; Jongkaewwattana, Anan; Auewarakul, Prasert
Fonte: J Virol;90(9): 4637-46, 2016 May.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26912622
Resumo: UNLABELLED: Human bronchoalveolar fluid is known to have anti-influenza activity. It is believed to be a frontline innate defense against the virus. Several antiviral factors, including surfactant protein D, are believed to contribute to the activity. The 2009 pandemic H1N1 influenza virus was previously shown to be less sensitive to surfactant protein D. Nevertheless, whether different influenza virus strains have different sensitivities to the overall anti-influenza activity of human bron (mais)
Resultados  1-12 de 53